{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045997","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.274347+00:00","generated_at":"2026-05-30T04:11:01.809735+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vericel Q3 revenue up 27% to $57.9M; raises full-year margin guidance","bullets":["Total net revenue $57.9M (+27% YoY); MACI $44.7M (+19%), Burn Care $13.2M (+66%).","Gross margin 72% (+480bps YoY); net loss narrowed to $0.9M ($0.02/share) from $3.7M.","Adjusted EBITDA $10.0M (+84%, margin 17%); raised FY24 guidance: gross margin 72%, adj. EBITDA margin 22%.","FDA approved MACI Arthro for knee cartilage repair; NexoBrid pediatric indication also approved.","Cash $151M, no debt; operating cash flow $10.2M in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045997","json":"https://secwatch.observer/filing/0001628280-24-045997.json","markdown":"https://secwatch.observer/filing/0001628280-24-045997.md","text":"https://secwatch.observer/filing/0001628280-24-045997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828024045997/0001628280-24-045997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828024045997/vcel-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:11:01.809735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}